title: Caspofungin in the treatment of oropharyngeal candidiasis.
abstract: A patient with AIDS developed oropharyngeal candidiasis. Candida albicans and C. glabrata were isolated from the patient and found to be resistant to fluconazole and itraconazole in vitro. Voriconazole therapy was initiated, but discontinued when the C. albicans strain isolated from the patient was found to be resistant to it. The patient failed to respond to subsequent therapy with a combination of amphotericin B and 5-flucytosine. Therapy with caspofungin was then initiated (70 mg loading dose, followed by 50 mg/day). The patient responded favourably to caspofungin, with complete resolution of signs and symptoms.
authors.affiliation: Division of Infectious Diseases, University of Geneva Hospitals, Geneva, Switzerland.
authors.forename: J
authors.initials: J
authors.lastname: Garbino
authors.forename: D
authors.initials: D
authors.lastname: Lew
authors.forename: B
authors.initials: B
authors.lastname: Hirschel
authors.forename: P
authors.initials: P
authors.lastname: Rohner
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D002180:Candidiasis, Oral / Q000188:drug therapy*; D000077336:Caspofungin; D025141:Drug Resistance, Fungal; D054714:Echinocandins; D006801:Humans; D055666:Lipopeptides; D008297:Male; D008875:Middle Aged; D010455:Peptides; D010456:Peptides, Cyclic; D010608:Pharyngeal Diseases / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D000077336:Caspofungin